权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Real-time genetic reprogramming of micron-scale soft matter devices

微米级软物质装置的实时基因重编程

基本信息

批准号：
2851929
负责人：
金额：
--
依托单位：
Imperial College London
依托单位国家：
英国
项目类别：
Studentship
财政年份：
2022
资助国家：
英国
起止时间：
2022 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=studentship-2851929
关键词：
Real time genetic reprogramming micron

项目摘要

One of the defining featured of living cells which underpins their utility in biotechnological applications is their ability to be reprogrammed through genetic modification. This feature has led to the rise of synthetic biology in application areas including biomedicine, sensing, bioproduction, and environmental remediation. Synthetic cells are increasingly being recognised as a powerful alternative to biological cells, due to inherent limitations associated with working with living systems. However, to date, methods to reprogramme synthetic cells are not yet available: further modification of their genetic makeup, once generated, is not possible. As synthetic cells are nearing deployment in real-world settings, this is presenting itself as a bottleneck. In this project we will develop technologies to remedy this. We will explore how new genetic software can be delivered to synthetic cell hardware, which allow them to undergo a process of differentiation. In this way, we will show that the same synthetic cell can be used as a bioreactor, sensor, antimicrobial, anti-cancer, and vaccine agent, depending on its context. The project will involve the development and characterisation new microfluidic, biomembrane, and chemical biology tools which will enable the creation of reprogrammable synthetic cell microdevices, based on soft matter materials.

活细胞在生物技术应用中的定义特征之一是它们通过遗传修饰重新编程的能力。这一特点导致合成生物学在生物医学、传感、生物生产和环境修复等应用领域的兴起。由于与生命系统相关的固有限制，合成细胞越来越被认为是生物细胞的强大替代品。然而，到目前为止，重新编程合成细胞的方法还不存在：一旦生成，就不可能进一步修改它们的基因组成。随着合成细胞接近在现实世界中的部署，这将成为一个瓶颈。在这个项目中，我们将开发技术来解决这个问题。我们将探索如何将新的遗传软件交付给合成细胞硬件，使它们能够经历分化过程。通过这种方式，我们将证明相同的合成细胞可以根据其背景用作生物反应器，传感器，抗菌剂，抗癌剂和疫苗剂。该项目将涉及新的微流体，生物膜和化学生物学工具的开发和表征，这将使基于软物质材料的可重新编程合成细胞微器件的创建成为可能。